(Times of Israel) Shoshanna Solomon - "Roughly almost half of (our) healthcare revenue is based on innovation stemming from Israel," Kai Beckmann, CEO of Performance Materials at Germany's Merck pharmaceutical and chemicals firm, said in an interview on Tuesday. The Rebif drug marketed by Merck to help decrease the frequency of relapse symptoms of multiple sclerosis had sales of 1.7 billion euros in 2016, while the Erbitux drug for patients with cancer of the head and neck, also based on Israeli technology, had global sales of 1 billion euros. Beckmann was in Israel to inaugurate a new technology innovation laboratory at its subsidiary, Qlight Nanotech, in Jerusalem.
2018-02-09 00:00:00Full ArticleBACK Visit the Daily Alert Archive